Wereported the first case of hypersensitivity pneumonitis (HP) by an edible mushroom, Pleurotus Eryngii (Eringi). A 54-year-old womanhad worked in a Bunashimeji mushroom factory for 42 months, and she movedto a new factory producing Eringi. Twomonths after, she was found to have HPby the spore of Eringi. Although no radiological finding was detected 6 months before the onset of HP, serum surfactant protein D (SP-D) had been elevated. We speculated that type II pneumocyte activation might prepare the ground for HP during the former exposure to Bunashimeji, and serum SP-D levels might reflect their conditions. (Internal Medicine 41: 571-573, 2002) 
Introduction
Hypersensitivity pneumonitis (HP) caused by inhalation of the mushroomspore itself has increased (1-7), and HPhas been described as an occupational hazard of mushroomplant workers. Surfactant protein D (SP-D) is synthesized in type II pneumocytes and non-ciliated bronchiolar epithelium, and is one of the useful serum markers of disease activity for idiopathic pulmonary fibrosis, interstitial pneumonia with collagen disease, and pulmonary alveolar proteinosis (PAP), and HP (5, 8) . Wereported the first case of occupational HPcaused by an edible mushroom, Pleurotus Eryngii (Eringi), and found that serum SP-D levels had already been elevated 6 months before the onset of HP.
Case Report
A 54-year-old, non-smoker visited our hospital because of an increase of dyspnea and severe cough. The patient's medical history and her family history gave negative findings. She began to work in a mushroomplant producing Bunashimeji in May 1995. After 13 months, she noted slight cough and sputum at work place. She first visited our hospital on June 1998 for these symptoms. There were no abnormal findings in physical examination, routine laboratory studies, arterial blood gas analysis, chest roentgenogram, and chest computed tomographic (CT) scans. However, serum SP-D level was high (230 ng/ml; cut off level is 1 10 ng/ml). She had been treated as having chronic bronchitis. She movedto a newmushroomplant producing Eringi in December 1998. Two months later, she complained of an increase of severe cough, sputum, dyspnea, and general malaise. She visited our hospital again and was admitted in February 1999. On admission, a chest roentgenogram showed bilateral diffuse reticulo-nodular shadows ( Fig.  1 ). Chest CT scans showed bilateral diffuse ground glass attenuation and nodular opacities ( Fig. 2 ). Serum SP-D level was 280 ng/ml. Respiratory function test demonstrated a decrease in carbon monoxide diffusing capacity (78.0% of predicted), however vital capacity, forced expiratory volume in 1 second, and the airway responsiveness to methacholine were within the normal range. Bronchoalveolar lavage (BAL) fluid from the right middle lobe demonstrated an increase of total cells (2.3xlO6/ml), lymphocytes (48.7% of the total cells), and eosinophils (3.9%). CD4/CD8ratio of lymphocyte surface markers was 1.8. Transbronchial lung biopsy specimen showed lymphocyte infiltration in the alveoli. Double immunodiffusion analysis was performed to screen for the presence of antibodies to extracts of the Bunashimeji and Eringi spores. The method had been previously described (5) . Precipitin lines appeared in both Bunashimeji and Eringi antigens, but none line was observed in Micropolyspora Faeni, Thermoactimomyces Vulgaris, and Aspergillus Fumigatus. Next, we performed lymphocyte stimulating test using peripheral blood cells as previously described (1) . A positive response in peripheral blood lymphocytes was observed to the Eringi antigens ( cells. Microscopic view of the spores of Eringi is shown in Fig. 3 . The shape of the spore was ellipsoid and the size was 3-4x7-8 |Lim, which enables reach of the terminal airway and alveoli. From these findings, she was found to have HPcaused by inhalation of the Eringi spore. She was treated with daily 40 mg of prednisolone. Her symptoms, findings of chest roentgenogram and CT images markedly improved, and the levels of serum SP-Ddecreased to within the normal range after prednisolone therapy. The dose of prednisolone was gradually tapered and discontinued in May2000. She quit the work at the mushroomplant, and after that no respiratory symptomshave been observed. Figure 2 . Chest computed tomographic scan shows bilateral ground grass attenuation and nodular opacities. HP by Pleurotus Eryngii (Eringi)
Discussion
There have been only 12 cases of HP caused by mushroom spores in the literature: Pholiota Nameko (Nameko) (1, 2), Lentinus Edodes (Shiitake) (3, 4) , Hypsizigus Marumoreus (Bunashimeji) (5), Oyster mushroom (6) . There has been no report of HP induced by the spores of Eringi, and this is the first case. The spore size of Eringi is small enough to reach the bronchiole and alveoli, therefore inhalation of this spore can cause HP. SerumSP-Dlevel had been elevated six months before the onset of HP in the present case. SP-D is synthesized both in type II pneumocytes and in non-ciliated bronchiolar epithelium. Wepreviously reported that serum SP-Dlevels were a useful marker for disease activity of HPcaused by the spore of Bunashimeji (5) . It was reported that surfactant protein A, a marker of interstitial lung disease, is elevated in BALfluid in HP patients (9) . However, in some HP cases, SP-D values in BALfluid are not elevated (not published data). Therefore, it was speculated that increased serum SP-D might be due to the following two reasons; 1) activation of SP-D production in type II cell pneumocytes or peripheral airway epithelium induced by the stimulation of Eringi spore or some other stimuli (i.e. environment endotoxin), or 2) increased permeability of lung structure.
Atwo-month period seems too short from the sensitization to the onset of HPin the present case, as the reported periods were from 2 to 13 years in HPcaused by mushroomspores (10, 1 1) . Our patient had been engaged in cultivating Bunashimeji mushroomfor 42 months before the onset of HP. Although she had positive serum precipitins to Bunashimeji antigens, there was a negative result of lymphocytestimulating test both in BALand in peripheral blood cells. On the other hand, dairy farmers, not diagnosed as HP, with positive serum precipitins for the causative antigens had an increase of lymphocytes in BALfluid (12), suggesting lymphocyte alveolitis. Persistent contact with a farm environment might maintain a state of alveolar lymphocytosis, and this speculation is supported by the fact that subjects with previous farmer's lung who left the farm had a lower lymphocyte percentage in their BALfluid as compared with subjects whostayed in contact (12) . Here, since there was no finding on the CTscans 6 months before the on-set of HP, it was suggested that our patient had experienced non-specific illness probably associated with lymphocyte alveolitis caused by inhalation of Bunashimeji spores, which might not be HPbut rather a preparation stage of HP. Therefore, this illness might induce a rapid response to new mushroom antigens, or increased permeability of lung structure might shorten the sensitization time of Eringi antigens. Taken together, it was speculated that the former exposure of Bunashimeji spores could cause non-specific lymphocytealveolitis, which might prepare the ground for HP, and this might have an important role in the shortening of the latent time for HPto occur.
